Test filters

News

In the media

Press releases

Publications

Scientific articles

Statements

Stories

Videos

Viewpoints

Stories

20 Aug 2026

Mycetoma at 10: What recognition made possible

Scientific articles

15 Aug 2026

Identification of new Trypanosoma cruzi-specific protein synthesis inhibitors by using a developed high-throughput in vitro translation assay

International Journal for Parasitology: Drugs and Drug Resistance

Scientific articles

5 Aug 2026

ICH E21: from landmark guidance to specific action for maternal and child health

Scientific articles

3 Aug 2026

A Phase IIa, Proof-of-Concept, Placebo-Controlled, Randomised Trial to Investigate the Efficacy and Safety of Oxfendazole as a Macrofilaricidal Drug in Adults Harbouring Lymphatic Filarial Worms

Infectious Diseases and Therapy

Viewpoints

3 Aug 2026

A new chapter for African medical innovation

Nature Africa

In the media

1 Aug 2026

End of painful injections as Kenya set to adopt new 14-day Kala-azar treatment

Daily Nation

In the media

30 Jul 2026

WHO approves new shorter, less painful Kala-azar treatment for East Africa

New Vision

Viewpoints

30 Jul 2026

Ten years after WHO recognition, mycetoma remains one of the world’s most neglected diseases

Stat News

Press releases

29 Jul 2026

WHO recommends new, better and safer treatment regimens for leishmaniasis

Press releases

27 Jul 2026

DNDi leadership to change in 2027

In the media

21 Jul 2026

How Scientists Can Revive Global Health Drug Development

Think Global Health

Stories

16 Jul 2026

Annie Liang: How students’ advocacy helped bring mycetoma out of the shadows

Publications

16 Jul 2026

DNDi 2025 Annual Report

In the media

15 Jul 2026

Dengue outbreak complicates Bangladesh measles crisis response

The Telegraph

Press releases

13 Jul 2026

DNDi welcomes continued GHIT support for collaboration on dengue and Zika virus drug discovery with Eisai and new partner, the Japan Institute for Health Security

Press releases

13 Jul 2026

DNDi welcomes GHIT support to advance novel oral drug candidate for leishmaniasis, accelerating progress towards elimination goals

International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Mycetoma at 10: What recognition made possible

Identification of new Trypanosoma cruzi-specific protein synthesis inhibitors by using a developed high-throughput in vitro translation assay

ICH E21: from landmark guidance to specific action for maternal and child health

A Phase IIa, Proof-of-Concept, Placebo-Controlled, Randomised Trial to Investigate the Efficacy and Safety of Oxfendazole as a Macrofilaricidal Drug in Adults Harbouring Lymphatic Filarial Worms

A new chapter for African medical innovation

End of painful injections as Kenya set to adopt new 14-day Kala-azar treatment

WHO approves new shorter, less painful Kala-azar treatment for East Africa

Ten years after WHO recognition, mycetoma remains one of the world’s most neglected diseases

WHO recommends new, better and safer treatment regimens for leishmaniasis

DNDi leadership to change in 2027

How Scientists Can Revive Global Health Drug Development

Annie Liang: How students’ advocacy helped bring mycetoma out of the shadows

DNDi 2025 Annual Report

Dengue outbreak complicates Bangladesh measles crisis response

DNDi welcomes continued GHIT support for collaboration on dengue and Zika virus drug discovery with Eisai and new partner, the Japan Institute for Health Security

DNDi welcomes GHIT support to advance novel oral drug candidate for leishmaniasis, accelerating progress towards elimination goals

Learn more

Get in touch

Support us

Work with us